This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875534. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, and Obesity Action Coalition.
SOPHIA General Assembly meeting 2022
The 28th of April 2022 we had the pleasure to host our 2nd yearly SOPHIA General Aseembly meeting at Favrholm Campus in Denmark. The video will show a recap of a fantastic day.
To understand the rose, one person may use geometry and another the butterfly
The theme of this year’s World Obesity Day was ‘everybody needs to act’. On the day itself we saw clear and compelling accounts from advocacy groups, scientific contributions from leading medics and researchers, and policy recommendations from think-tanks and NGOs. The message was clear – to develop an effective understanding of, and response to, obesity as a chronic disease, everybody needs to act.
Systematic review video for twitter
Press Release- IMI SOPHIA partners with Maccabi’s research and innovation center (KSM), Pfizer, and Lausanne University Hospital to improve obesity treatment
IMI SOPHIA is pleased to announce an agreement with Maccabi Research and Innovation Center (KSM), Pfizer, and the Lausanne University Hospital to initiate activities for the public-private research consortium ‘SOPHIA (Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy), a €16-million EU-supported international research consortium that aims to improve obesity treatment and change the narrative around obesity.
KSM, Pfizer, and the Lausanne University Hospital will join SOPHIA’s 29 other partners from civil society, academia, and industry with the aim to better understand obesity as a chronic disease and optimise future treatment.
Call for meeting name submissions
“Did you also experience FOMO on that Microsoft Teams meeting?” FOMO stands for Fear of Missing Out and is defined in the dictionary as: “the worried feeling that you may miss exciting events that other people are going to”. In the current environment where digital fatigue has become another symptom of COVID-19, you might think that the opening question is more of an oxymoron, an alluring figure of speech in order to capture your attention as a reader.
Words matter: addressing obesity together
How I Looked Beyond the Stars
dedicated four years of a mathematics PhD to studying the distant (1.5×10^8m away to be precise) mass we refer to as ‘The Sun’, desperately trying to make or simulate complicated measurements that my peers wouldn’t instantly disbelieve. Nevertheless, I felt an urge to study a subject somewhat closer to my home. Maybe one that might have an impact on my own environment, where I live and thrive, my family, or even the local shopkeeper’s. Basically anything where I didn’t have to show patience for the next ten billion years to see an effect.
Change your mind: obesity and type 1 diabetes
Diabetes is a chronic disease of carbohydrate, fat and protein metabolism that results from the inadequate action of insulin. It affects an estimated 463 million people worldwide and is predicted to rise to approximately 578 million people by 20301. Dangerous acute complications of diabetes include diabetic ketoacidosis and severe hypoglycemia (low blood glucose), which can lead to a trip to the emergency room or worse. In the long-term, chronic hyperglycemia (high blood glucose) can lead to a number of micro- and macro- vascular complications, including nephropathy, retinopathy, coronary artery disease, stroke and peripheral neuropathy.
Obesity, a risk factor for symptom severity
The main topic of interest within SOPHIA’s WP3 is to assess the risk factors involved in obesity. However, obesity itself is a well-known risk factor of other diseases. For example, obesity has been considered a long-term risk factor for chronic diseases such as cardiovascular disease and diabetes; on the other hand, obesity is considered a risk factor for acute diseases as well.
The foundation for analysis across cohorts: a common data model
One of the objectives within SOPHIA WP2 is to harmonise and standardise obesity cohorts and link them into a federated database system to allow for analysis across cohorts. The crucial benefit of the federated database is that the individual cohorts can stay locally on edge nodes, while a central server along with specialized software can learn models across nodes, while preserving privacy and security.
“I am terrified of something happening to me” The lived experience of people with obesity during the COVID‐19 pandemic
Congratulations to Work Package 7 working group for publishing some of their research work carried out as part of SOPHIA. The research highlights the lived experiences of people living with obesity during the COVID-19 pandemic. It highlights the challenge sustaining treatment and psychosocial impact during these unprecedented times.
A Q&A about SOPHIA with Prof. Carel le Roux
The Innovative Medicine Initiative has published an article about the work we do in SOPHIA and it impacts on the diabetes epidemic. The article includes a Q&A with Prof Carel le Roux, Project Coordinator.